A single dose of rituximab does not deplete b cells in secondary lymphoid organs but alters phenotype and function

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1503-1511

  Kamburova, E G ^a,b   Koenen, H J P M ^a,b   Borgman, K J E ^a,b   Ten Berge, I J ^c   Joosten, I ^a,b   Hilbrands, L B ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

B cell; lymph node; rituximab; T cell

Indexed keywords

CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CYTIDINE DEAMINASE; IMMUNOGLOBULIN D; INTERLEUKIN 21; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; FEMALE; GRAFT RECIPIENT; HUMAN; IN VITRO STUDY; KIDNEY GRAFT; LYMPH NODE; MALE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH17 CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PHENOTYPE; SPLEEN; T-LYMPHOCYTES;

EID: 84878519724     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12220     Document Type: Article

References (40)

1. Jordan SC, Kahwaji J, Toyoda M, Vo A., B-cell immunotherapeutics: Emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011; 16: 416-424.
2. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in man that parallels mouse regulatory B10 cells. Blood 2010; 117: 530-541.
3. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
4. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
5. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43.
6. Glennie MJ, French RR, Cragg MS, Taylor RP., Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-3837.
7. Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G., Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009; 9: 82-89.
8. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP., Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-925.
9. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS ? Ann Neurol 2010; 67: 452-461.
10. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91: 853-857.
11. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102.
12. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277-1280.
13. Audia S, Samson M, Guy J, et al. Immunological effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011; 118: 4394-4400.
14. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP., The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-407.
15. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G., Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
16. Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I., In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012; 12: 341-350.
17. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I., ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-148.
18. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I., Human CD25 high Foxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-2352.
19. Cragg MS, Bayne MB, Tutt AL, et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004; 104: 2540-2542.
20. Avery DT, Bryant VL, Ma CS, de Waal MR, Tangye SG., IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008; 181: 1767-1779.
21. Honjo T, Kinoshita K, Muramatsu M., Molecular mechanism of class switch recombination: Linkage with somatic hypermutation. Annu Rev Immunol 2002; 20: 165-196.
22. Nakou M, Sidiropoulos P, Bertsias G, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: Depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009; 11: R131.
23. Vos K, Thurlings RM, Wijbrandts CA, van SD, Gerlag DM, Tak PP., Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-778.
24. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85: 1648-1653.
25. Barbera-Guillem E, Nelson MB, Barr B, et al. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000; 48: 541-549.
26. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
27. Sugiura H, Takei T, Itabashi M, et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011; 117: c98-c105.
28. Wermke M, von Bonin M, Gehrisch S, Siegert G, Ehninger G, Platzbecker U., Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab. Haematologica 2010; 95: 521-522.
29. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514-3520.
30. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ., Apparent modulation of CD20 by rituximab: An alternative explanation. Blood 2004; 103: 3989-3990.
31. Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011; 187: 3438-3447.
32. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood 2010; 115: 5191-5201.
33. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-3288.
34. Good KL, Avery DT, Tangye SG., Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol 2009; 182: 890-901.
35. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63: 1507-1516.
36. Barbosa RR, Silva SP, Silva SL, et al. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS ONE 2011; 6: e22848.
37. Carpenter EL, Mick R, Rech AJ, et al. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009; 15: 4277-4287.
38. Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FH, Mulder A., Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009; 158: 99-105.
39. Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, Jacobi AM., Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R110.
40. Fukuda R, Ichikawa Y, Takaya M, Ogawa Y, Masumoto A., Circadian variations and prednisolone-induced alterations of circulating lymphocyte subsets in man. Intern Med 1994; 33: 733-738.